Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugging p53: Barriers, Criteria, and Prospects.

Cancer discovery - 1 Nov 2024

Song Huaxin, Xiao Shujun, Wu Jiaqi, Lu Min

Abstract excerpt

Pharmacologically targeting tumor suppressors necessitates an unprecedented strategy of restoring, rather than conventionally inhibiting, protein function, and p53, the most commonly mutated protein in cancer, has thus remained undruggable. In this study, we address long-standing misconceptions in the field and gaps in the scientific logic for a p53 function-restoration strategy, identify four barriers for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cancer, Hypoxia, and Metabolism
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Research and Treatments

Share to Mutation

Share to Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 39485253
DOI: 10.1158/2159-8290.CD-24-0837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging p53: Barriers, Criteria, and Prospects.PMID 39485253Read ↗

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy - Drug RepurposingSemantic proximity Read ↗

Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible.Semantic proximity Read ↗

Drugging p53 in cancer: one protein, many targets.Semantic proximity Read ↗

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.Semantic proximity Read ↗

Drugging the p53 pathway: understanding the route to clinical efficacySemantic proximity Read ↗

A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.Semantic proximity Read ↗

Shifting the paradigms for tumor suppression: lessons from the p53 field.Semantic proximity Read ↗

Rescuing the function of mutant p53.Semantic proximity Read ↗

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.Semantic proximity Read ↗

Improving cancer therapy through p53 management.Semantic proximity Read ↗

Side-Stepping the Guardian of the Genome: Current Cancer Therapeutics Targeting Mutant p53Semantic proximity Read ↗

Reviving the guardian of the genome: Small molecule activators of p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.